Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the sale, the chief financial officer owned 38,000 shares in the company, valued at $1,913,300. This trade represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total value of $352,534.44.
• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total value of $316,787.52.

Enliven Therapeutics Trading Down 1.2%

Shares of ELVN traded down $0.58 during trading hours on Monday, reaching $48.87. 2,281,264 shares of the company’s stock traded hands, compared to its average volume of 1,268,609. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The stock has a market cap of $3.58 billion, a PE ratio of -29.26 and a beta of 0.30. The firm’s 50 day simple moving average is $56.43 and its 200-day simple moving average is $46.17.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth $38,000. State of Wyoming purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth $96,000. FNY Investment Advisers LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth $126,000. Seven Fleet Capital Management LP bought a new stake in shares of Enliven Therapeutics in the fourth quarter worth $180,000. Finally, Royal Bank of Canada grew its holdings in shares of Enliven Therapeutics by 345.0% in the first quarter. Royal Bank of Canada now owns 5,424 shares of the company’s stock worth $212,000 after acquiring an additional 4,205 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

ELVN has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. The Goldman Sachs Group raised their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Guggenheim dropped their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.